Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercialization
LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) today announced that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer. This will enable increased R&D productivity for Immunovia as the Company continues to strengthen its commercial development in the US. The partnership between Immunovia and Proteomedix leverages the companies’ complementary R&D capabilities and advances their R&D efforts. With this partnership, Immunovia will gain a more flexible R&D